Generic Versus Branded Medicines Available on the Local Market
This paper presents a survey study of generic and branded medicines available on the local market. The study was carried out on solid dosage forms (Tablets and capsules) for 53 medications available at the time of study in 69 pharmacies located in Tripoli, Libya. Physical specifications (generic name, batch number, manufacture date, expiry date and the manufacturer) as appeared on the package for each product were recorded in a designed form. The retail price at the time of study for each innovator brand and the counterpart generic was also recorded and compared. Results showed that 234 (89%) generics and 29 (11%) branded medicines were available for the studied medicines. The generics medicines were antibiotics (28%), cardiovascular (24.36%), analgesics and antipyretics (12.5%), gastrointestinal (12.8%), for respiratory tract (0.85%), anti-Anthistamin (7.26%), for adiabatic (3%), for vitamins and minerals (6%) and corticosteroid (1%) medicines. The original suppliers of the generics were European countries (42%), Arabian countries (41%) and other region of the world (17%). The retail prices for the generics were significantly (p > 0.05) lower compared to the price of innovator brand counterpart. The study suggests post-marketing surveillance studies for the available generics in comparison to the innovators especially in terms of therapeutic efficiency.
Ameri, M.N.A., et al., (2012); The differences between the branded and generic medicines using solid dosage forms: In-vitro dissolution testing; Results in Pharma Sciences; 2; 1-8.
Antonio, P., et al (2004); Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers; Current Therapeutic Research; 65(1); 34-46.
Bagheri H., Garraffo R., and Dellamonica P (2014); From antiretroviral originator to generic drugs: Bioequivalence and pharmacovigilance; Médecine et maladies infectieuses; 44(10); 464-469.
Dunne S., et al., (2013); A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study; BMC Pharmacology and Toxicology; 14(1); 1-19
Fischer, M. and Avorn J (2004); Economic implications of evidence-based prescribing for hypertension: can better care cost less?; JAMA; 291(15); 1850–1856.
Fischer, M. and Avorn J (2004), " Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit"; Pharmacoepidemiol Drug Saf; 13(4); 207–214.
Gossell-Williams, M. (2007); Generic Substitutions: A 2005 Survey of the Acceptance and Perceptions of Physicians in Jamaica; West Indian Med J; 56(5); 458.
Kaiser H.J., (2001); Prescription Drug Trends—A Chart book Update; Menlo Park, CA.
Kesselheim, A.S., et al., (2008); Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis; JAMA; 300(21); 2514–2526.
Kjoenniksen, I., Lindbaek M., and Granas A. G (2006); Patients’ attitudes towards and experiences of generic drug substitution in Norway; Pharm World Sci; 28(5); 284-289.
Kohl H. (2007); Increasing generic drug use in Medicare Part D: The role of government; J Am Geriatr Soc; 55(7); 1106–1109.
Liu, Y.-M., Y.-H.K. Yang, and Hsieh C.R (2009); Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan; Journal of Health Economics; 28(2); 341-349.
Meredith P. (2003); Bioequivalence and Other Unresolved Issues in Generic Drug Substitution; Clinical Therapeutics; 25(11); 2875-2890.
Minghetti, P., (1996); Regulatory status of medicinal products for human beings in the European Union. The role of generic products; Pharmacological research; 34(1); 3-7.
Ngwuluka N.C., Olorunfemi K.L., and Ochekpe N.A (2009); Post-market in vitro bioequivalence study of six brands of ciprofloxacin tablets/caplets in Jos, Nigeria; Scientific Research and Essay; 4(4); 298-305.
Parvez, N., et al., (2009); Compartive bioavailability of three oral formulations of sustained release theophylline in healthy human subjects; Indian J Pharmacol; 36(1); 29-33.
Shaw, S.J. and Hartman A.L,(2010); The Controversy over Generic Antiepileptic Drugs; J Pediatr Pharmacol Ther;. 15(2); 81-93.
Skipper, N. and Vejlin R, (2015); Determinants of generic vs. brand drug choice: Evidence from population-wide Danish data; Social Science & Medicine; 130; 204-215.
Smaoui, F., Kilani F.A, and Touzani M. (2016); Country-of-origin versus brand: consumers’ dilemma when choosing between generic and branded drugs in emerging countries; Journal of Product & Brand Management; 25(2); 148-159.